Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AGHAEGBULAM H UGA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1083925945
CMS profile
1134639
Location
EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$20,392.69

111 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 111 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AGHAEGBULAM H UGA

NPI 1083925945 · CMS profile ID 1134639

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 111 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083925945?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AGHAEGBULAM H UGA, NPI 1083925945, CMS profile ID 1134639. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 111 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083925945?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). AGHAEGBULAM H UGA, NPI 1083925945, CMS profile ID 1134639. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 111 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083925945?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
AGHAEGBULAM H UGA, NPI 1083925945, CMS profile ID 1134639, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 111 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1083925945?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

111 matching records · $20,392.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 111 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 111.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $19.1806/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247491571 CMS
ABBVIE INC. $13.2606/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204594931 CMS
Alkermes, Inc. $17.6305/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222658372 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $18.7405/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241415314 CMS
Sage Therapeutics, LLC $15.8305/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211463051 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.6905/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223911373 CMS
Teva Pharmaceuticals USA, Inc. $16.9505/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247491551 CMS
Otsuka America Pharmaceutical, Inc. $24.1505/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227523756 CMS
ABBVIE INC. $18.0405/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204594928 CMS
Janssen Pharmaceuticals, Inc $65.0005/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174938713 CMS
Janssen Pharmaceuticals, Inc $382.2005/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174938844 CMS
E.R. Squibb & Sons, L.L.C. $25.6804/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184565777 CMS
ABBVIE INC. $26.0804/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204594924 CMS
Janssen Pharmaceuticals, Inc $3,200.0004/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174938578 CMS
Janssen Pharmaceuticals, Inc $24.4204/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174938029 CMS
Vanda Pharmaceuticals Inc. $15.6504/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233009757 CMS
Janssen Pharmaceuticals, Inc $126.0804/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174938086 CMS
Sage Therapeutics, LLC $13.7104/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211474269 CMS
Axsome Therapeutics, Inc. $12.1404/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235622858 CMS
Vanda Pharmaceuticals Inc. $16.8004/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233009755 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.2604/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223851146 CMS
Teva Pharmaceuticals USA, Inc. $9.8504/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247491549 CMS
Axsome Therapeutics, Inc. $33.7004/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235715314 CMS
Otsuka America Pharmaceutical, Inc. $11.1303/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227523752 CMS
E.R. Squibb & Sons, L.L.C. $24.0303/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184565763 CMS
Vanda Pharmaceuticals Inc. $17.8903/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233009753 CMS
Janssen Pharmaceuticals, Inc $14.4703/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174938634 CMS
Janssen Pharmaceuticals, Inc $7,560.0003/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174937468 CMS
ABBVIE INC. $22.2403/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204594919 CMS
Janssen Pharmaceuticals, Inc $2,750.0003/06/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174938805 CMS
Janssen Pharmaceuticals, Inc $15.5203/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174938067 CMS
Lundbeck LLC $13.7703/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251855397 CMS
Alkermes, Inc. $17.3302/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222658370 CMS
E.R. Squibb & Sons, L.L.C. $23.5902/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184565749 CMS
Janssen Pharmaceuticals, Inc $124.9902/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174939081 CMS
Lundbeck LLC $2.8802/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251855393 CMS
Lundbeck LLC $18.1602/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251855395 CMS
Vanda Pharmaceuticals Inc. $20.8202/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233009751 CMS
Teva Pharmaceuticals USA, Inc. $18.0902/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247491515 CMS
Janssen Pharmaceuticals, Inc $12.7002/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174937668 CMS
Janssen Pharmaceuticals, Inc $13.6802/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174937976 CMS
Janssen Pharmaceuticals, Inc $56.5702/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174938194 CMS
Janssen Pharmaceuticals, Inc $35.7802/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174938488 CMS
Janssen Pharmaceuticals, Inc $120.4402/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174937863 CMS
Janssen Pharmaceuticals, Inc $14.7102/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174938344 CMS
Janssen Pharmaceuticals, Inc $13.9202/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174938700 CMS
Janssen Pharmaceuticals, Inc $50.0002/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174938749 CMS
Janssen Pharmaceuticals, Inc $9.8102/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174939032 CMS
Janssen Pharmaceuticals, Inc $33.3302/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174939110 CMS
Janssen Pharmaceuticals, Inc $110.0402/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174938334 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,634.82 30
PY2020 $1,002.69 15
PY2021 $8,206.38 78
PY2022 $9,047.29 64
PY2023 $30,494.13 98
PY2024 $18,669.25 129
PY2025 $20,392.69 111

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $80,880.54 54

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Neurocrine BioSciences Inc. $2,310.25 12/04/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271519
Principal investigator 1 Neurocrine BioSciences Inc. $706.00 12/04/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274654
Principal investigator 1 Neurocrine BioSciences Inc. $1,577.50 11/04/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272843
Principal investigator 1 Neurocrine BioSciences Inc. $1,378.90 10/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150273197
Principal investigator 1 Neurocrine BioSciences Inc. $808.00 10/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274208
Principal investigator 1 Neurocrine BioSciences Inc. $156.00 09/18/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150276672
Principal investigator 1 Neurocrine BioSciences Inc. $108.00 09/18/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150277080
Principal investigator 1 Neurocrine BioSciences Inc. $767.60 09/04/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274368
Principal investigator 1 Neurocrine BioSciences Inc. $1,716.15 08/09/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272675
Principal investigator 1 Neurocrine BioSciences Inc. $808.00 08/09/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274206
Principal investigator 1 Neurocrine BioSciences Inc. $156.00 08/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150276666
Principal investigator 1 Neurocrine BioSciences Inc. $156.00 08/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150276668
Principal investigator 1 Neurocrine BioSciences Inc. $156.00 08/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150276670
Principal investigator 1 Neurocrine BioSciences Inc. $108.00 08/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150277076
Principal investigator 1 Neurocrine BioSciences Inc. $108.00 08/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150277078
Principal investigator 1 Neurocrine BioSciences Inc. $63.00 08/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150277618
Principal investigator 1 Neurocrine BioSciences Inc. $125.00 07/17/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150277012
Principal investigator 1 Neurocrine BioSciences Inc. $63.00 07/17/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150277616
Principal investigator 1 Neurocrine BioSciences Inc. $6,000.00 07/03/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150268134
Principal investigator 1 Neurocrine BioSciences Inc. $2,602.00 07/03/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271043
Principal investigator 1 Neurocrine BioSciences Inc. $1,983.05 07/03/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272219
Principal investigator 1 Neurocrine BioSciences Inc. $1,849.00 07/03/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272441
Principal investigator 1 Neurocrine BioSciences Inc. $1,849.00 07/03/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272443
Principal investigator 1 Neurocrine BioSciences Inc. $1,759.00 07/03/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272577
Principal investigator 1 Neurocrine BioSciences Inc. $1,494.00 07/03/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150273049
Principal investigator 1 Neurocrine BioSciences Inc. $1,100.00 07/03/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150273618
Principal investigator 1 Neurocrine BioSciences Inc. $808.00 07/03/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274204
Principal investigator 1 Neurocrine BioSciences Inc. $579.00 07/03/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274983
Principal investigator 1 Neurocrine BioSciences Inc. $579.00 07/03/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274985
Principal investigator 1 Neurocrine BioSciences Inc. $579.00 07/03/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274987
Principal investigator 1 Neurocrine BioSciences Inc. $2,469.00 06/07/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271281
Principal investigator 1 Neurocrine BioSciences Inc. $2,006.60 06/07/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272063
Principal investigator 1 Neurocrine BioSciences Inc. $1,985.00 06/07/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272199
Principal investigator 1 Neurocrine BioSciences Inc. $1,494.00 06/07/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150273045
Principal investigator 1 Neurocrine BioSciences Inc. $1,494.00 06/07/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150273047
Principal investigator 1 Neurocrine BioSciences Inc. $706.00 06/07/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274652
Principal investigator 1 Neurocrine BioSciences Inc. $579.00 06/07/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274979
Principal investigator 1 Neurocrine BioSciences Inc. $579.00 06/07/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274981
Principal investigator 1 Neurocrine BioSciences Inc. $2,602.00 05/08/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271041
Principal investigator 1 Neurocrine BioSciences Inc. $2,114.35 05/08/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271927
Principal investigator 1 Neurocrine BioSciences Inc. $1,985.00 05/08/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272195
Principal investigator 1 Neurocrine BioSciences Inc. $1,985.00 05/08/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272197
Principal investigator 1 Neurocrine BioSciences Inc. $579.00 05/08/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274977
Principal investigator 1 Neurocrine BioSciences Inc. $651.70 04/05/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274783
Principal investigator 1 Neurocrine BioSciences Inc. $40.40 04/05/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150277936
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $15,284.94 02/10/2024 Non-covered Recipient Entity
MEDICUS ALLIANCE CLINICAL RESEARCH ORG INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6 DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1118845350
Principal investigator 1 Neurocrine BioSciences Inc. $2,235.40 02/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271685
Principal investigator 1 Neurocrine BioSciences Inc. $1,849.00 02/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272439
Principal investigator 1 Neurocrine BioSciences Inc. $1,494.00 02/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150273043
Principal investigator 1 Neurocrine BioSciences Inc. $808.00 02/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274202
Principal investigator 1 Neurocrine BioSciences Inc. $579.00 02/02/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274973
Principal investigator 1 Neurocrine BioSciences Inc. $2,343.70 01/10/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271459
Principal investigator 1 Neurocrine BioSciences Inc. $1,985.00 01/10/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272193
Principal investigator 1 Neurocrine BioSciences Inc. $579.00 01/10/2024 Non-covered Recipient Entity
Haracec Clinical Research PLLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274975